Kiniksa Pharmaceuticals Third Quarter 2026 Earnings Conference Call - KINIKSA PHARMACEUTICALS INTERNATIONAL PLC

Financial Performance:

• Full-year 2026 revenue guidance raised to $1.045–1.050 billion, driven by ARCLYS (Arculus).
• Q3 2026 ARCLYS revenue reached $286 million, a 58% year-over-year increase.
• Q3 operating income was $54.2 million and net income was $47.3 million, both up significantly year-over-year.
• Collaboration profit increased 67% year-over-year to $211.6 million, outpacing sales growth.
• End-of-quarter cash balance stood at $568.8 million, with approximately $43 million in net cash generation for the quarter.
• Patient penetration rate in the 14,000 multiple-recurrence annual population reached 23% as of Q3 end.
• Prescriber base grew to 5,450 total prescribers, an increase of 450 quarter-over-quarter, with 30% being repeat prescribers.

Guidance and Future Outlook:

• 2026 Full-Year R&D expense guidance set at $160–170 million, reflecting KPL-387 development and pre-commercial manufacturing costs.
• 2026 Full-Year SG&A expense guidance set at $270–280 million to support commercial expansion and DTC campaigns.
• KPL-387 pivotal Phase 3 trial data expected in the second half of 2027, with a potential launch window of 2028–2029.
• KPL-1161 expected to enter Phase 1 clinical trials by the end of 2026.
• Strategy focuses on expanding ARCLYS penetration from current 23% into the total 40,000 annual patient population, including the 26,000 first-recurrence patients.
• Long-term goal is to establish a portfolio of multiple commercial products within the IL-1 alpha and beta inhibition franchise.

Business Segments and Product Lines:

• ARCLYS (Arculus): Core revenue driver; experiencing robust growth driven by increased adoption earlier in the disease course (post-NSAIDs/colchicine, pre-steroids).
• KPL-387: Monthly subcutaneous IL-1 alpha/beta inhibitor currently enrolling in pivotal Phase 3; designed to replace current therapies and offer once-monthly dosing via auto-injector.
• KPL-1161: Quarterly IL-1 alpha/beta inhibitor targeting the receptor; anticipated to unlock new chronic/lifelong disease states due to long-duration action.
• New Patient Agreements: 55% of patients exposed to the "Heart's Home" DTC campaign expressed strong motivation to discuss treatment with providers.
• Clinical Development: Transition study (212) for KPL-387 is designed to inform labeling on switching from NSAIDs, colchicine, steroids, and other biologics.

Market and Competitive Landscape:

• Market share penetration in recurrent pericarditis is growing, with ARCLYS now capturing ~20% of prescriptions in the first-recurrence group.
• 2025 ACC Concise Clinical Guidance supports earlier treatment with IL-1 alpha/beta inhibition; 50% of surveyed physicians now support this paradigm (double the rate from three years prior).
• AI-driven patient identification and targeted Direct-to-Consumer (DTC) campaigns are differentiating strategy from broad-spectrum DTC efforts.
• DTC campaign metrics show a 12-fold increase in website traffic and an 8-fold increase in engaged sessions compared to baseline.

Risks and Challenges:

• Forward-looking statements are subject to risks regarding the timing of KPL-387 data readout and potential delays in regulatory approval.
• Execution risks include the need to maintain high clinical enrollment rates in global Phase 3 trials and the successful scaling of DTC campaigns.
• Market adoption challenges involve shifting physician behavior to treat earlier in the disease course and convincing payers of the value of new product profiles (KPL-387).
• Capital allocation risks involve maintaining high bars for external M&A/BD opportunities despite strong cash positions.

Management Commentary and Tone:

• Management tone is highly confident and optimistic, emphasizing "robust growth," "strong momentum," and "jolly well positioned" status.
• CEO Sanj Patel highlighted the transition from building stages of growth to executing a leading franchise strategy.
• COO Ross Mote emphasized "value-driven investments" and the efficiency of the targeted DTC approach.
• CFO Mark Ragosa highlighted disciplined commercial investment and the profitability of the collaboration model.
• The team expressed pride in meeting with global investigators and the "massive momentum" in clinical operations.

Analyst Questions and Answers:

• Enrollment Dynamics (Anupam Remo, J.P. Morgan): Confirmed KPL-387 is enrolling and dosing globally; management attributes confidence to strong investigator excitement and a top-tier clinical operations team.
• Penetration Curve & Spend Efficiency (Edward Nash, Canaccord Genuity): Management noted no structural change in patient demographics; growth is driven by accessing dispersed patients via AI targeting and DTC; spend described as highly efficient for a rare disease.
• KPL-387 Strategy & KPL-1161 Indications (Paul Choi, Goldman Sachs): KPL-387 trial is a posology study to inform label transition protocols; target product profile (monthly liquid/auto-injector) shows 75% patient preference and 92% HCP prescribing likelihood over current therapies. KPL-1161 indications not yet finalized but aimed at chronic conditions.
• Prescriber Mix (Roger Song/Jefferies): Did not share specific new patient split but noted 450 new prescribers added in Q3; 30% of prescribers are repeat customers.
• Patient Profiles & Capital Allocation (Jeff Meacham, Citi): KPL-387 offers optionality for patients on various current therapies; management remains pragmatic and selective on BD opportunities, prioritizing internal growth and value creation.

Other Key Points:

• The "Heart's Home" DTC campaign utilizes AI to produce and deliver content specifically for a rare disease audience.
• Approximately 50% of prescriptions are currently going to patients with first recurrence, despite the label focus on multiple recurrence.
• The company has "homegrown" its pipeline assets (KPL-387 and KPL-1161) but remains open to external value-creating opportunities.
• The 212 study (KPL-386 transition study) will evaluate switching patients from NSAIDs, colchicine, corticosteroids, anakinra, and rilonacept to KPL-387.